Zobrazeno 1 - 10
of 71
pro vyhledávání: ''
Publikováno v:
Gut and Liver. 16:147-156
Although Helicobacter pylori infection is the most important causative factor for gastric cancer (GC), H. pylori eradication alone does not completely eliminate the GC risk. In addition to H. pylori eradication, other risk factors for GC should be id
Publikováno v:
Gut and Liver
Background/aims Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated, especially among Asians.
Publikováno v:
Gut and Liver. 15:887-894
Background/aims To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatit
Autor:
Ali Khomsan, Kartika Afrida Fauzia, Langgeng Agung Waskito, I Ketut Adnyana, Muhammad Miftahussurur, Dalla Doohan, Neneng Ratnasari, Yudith Annisa Ayu Rezkitha, Isna Mahmudah
Publikováno v:
Gut and Liver. 15:653-665
Helicobacter pylori infects more than half the human population. However, the prevalence in Indonesia is low, as is the prevalence of gastric cancer. Hence, it could be instructive to compare these prevalence rates and their determining factors with
Autor:
Seung Yong Shin, Jong Pil Im, Sung Noh Hong, Eun Ae Kang, Soo-Kyung Park, Joo Hye Song, You Sun Kim, Ki Bae Bang, Hong Sub Lee, Kyeong Ok Kim, Eun Mi Song, Sang-Bum Kang, Chang Hwan Choi
Publikováno v:
Gut and Liver. 15:752-762
Background/Aims: Our study aimed to evaluate the long-term outcomes and risk factors for relapse after anti-tumor necrosis factor (TNF)-α cessation in inflammatory bowel disease (IBD) patients because they are not well established. Methods: A retros
Publikováno v:
Gut and Liver
Background/Aims Anti-drug antibodies (ADAs) can develop during treatment with anti-tumor necrosis factor (TNF) agents. We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with inflammatory bowel
Publikováno v:
Gut and Liver
The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no headto- head comparison of treatment efficacy and outcomes between the two agents. Th
Autor:
Young Mi Hong, Young Joo Park, Gwang Ha Kim, Mong Cho, Sang Gyu Park, Dong Uk Kim, Hyun Young Woo, Jeong Heo, Hyung Hoi Kim, Ki Tae Yoon, Geun Am Song
Publikováno v:
Gut and Liver. 15:440-450
Background/aims Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P
Autor:
Young Kul Jung, Ju Hyun Kim, Chan Uk Lee, Hyung Joon Yim, Seung Kak Shin, Jong Eun Yeon, Sang Jun Suh, Jeong Han Kim, Yun Soo Kim, Oh Sang Kwon
Publikováno v:
Gut and Liver
Background/Aims The clinical significance of partial virological response (PVR) in patients undergoing antiviral therapy is not well known. This study investigated whether PVR after 2 years of entecavir (ETV) therapy is associated with hepatocellular
Publikováno v:
Gut and Liver. 15:232-242
Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no head-to-head comparison of treatment efficacy and outcomes between t